ABG Sundal Collier acted as financial advisor to SpinChip Diagnostics and its shareholders in the NOK 1,624 million sale to bioMérieux

On 13 January 2025, SpinChip Diagnostics ASA (“SpinChip”) announced its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a total enterprise value of NOK 1,624 million.
Since its founding in 2012, SpinChip has developed a revolutionary in vitro diagnostics platform capable of rapidly conducting a wide range of tests across therapeutic areas such as cardiovascular, inflammatory/sepsis, infectious and endocrine diseases. With this, SpinChip’s technology aims to enhance diagnostic efficiency for patients and physicians while reducing healthcare costs.
ABGSC acted as financial advisor to SpinChip and its shareholders and would like to extend our gratitude for the vote of confidence.